95 related articles for article (PubMed ID: 12383884)
1. Antipruritic and antihyperalgesic actions of loperamide and analogs.
DeHaven-Hudkins DL; Cowan A; Cortes Burgos L; Daubert JD; Cassel JA; DeHaven RN; Kehner GB; Kumar V
Life Sci; 2002 Oct; 71(23):2787-96. PubMed ID: 12383884
[TBL] [Abstract][Full Text] [Related]
2. Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity.
DeHaven-Hudkins DL; Burgos LC; Cassel JA; Daubert JD; DeHaven RN; Mansson E; Nagasaka H; Yu G; Yaksh T
J Pharmacol Exp Ther; 1999 Apr; 289(1):494-502. PubMed ID: 10087042
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the antihyperalgesic action of a novel peripheral mu-opioid receptor agonist--loperamide.
Nozaki-Taguchi N; Yaksh TL
Anesthesiology; 1999 Jan; 90(1):225-34. PubMed ID: 9915332
[TBL] [Abstract][Full Text] [Related]
4. Development of an effective topical liposomal formulation for localized analgesia and anti-inflammatory actions in the Complete Freund's Adjuvant rodent model of acute inflammatory pain.
Iwaszkiewicz KS; Hua S
Pain Physician; 2014; 17(6):E719-35. PubMed ID: 25415787
[TBL] [Abstract][Full Text] [Related]
5. SA14867, a newly synthesized kappa-opioid receptor agonist with antinociceptive and antipruritic effects.
Tsukahara-Ohsumi Y; Tsuji F; Niwa M; Nakamura M; Mizutani K; Inagaki N; Sasano M; Aono H
Eur J Pharmacol; 2010 Nov; 647(1-3):62-7. PubMed ID: 20813108
[TBL] [Abstract][Full Text] [Related]
6. Combination of a δ-opioid Receptor Agonist and Loperamide Produces Peripherally-mediated Analgesic Synergy in Mice.
Bruce DJ; Peterson CD; Kitto KF; Akgün E; Lazzaroni S; Portoghese PS; Fairbanks CA; Wilcox GL
Anesthesiology; 2019 Sep; 131(3):649-663. PubMed ID: 31343460
[TBL] [Abstract][Full Text] [Related]
7. Antihyperalgesic effects of loperamide in a model of rat neuropathic pain are mediated by peripheral delta-opioid receptors.
Shinoda K; Hruby VJ; Porreca F
Neurosci Lett; 2007 Jan; 411(2):143-6. PubMed ID: 17110034
[TBL] [Abstract][Full Text] [Related]
8. Binding site of loperamide: automated docking of loperamide in human mu- and delta-opioid receptors.
di Bosco AM; Grieco P; Diurno MV; Campiglia P; Novellino E; Mazzoni O
Chem Biol Drug Des; 2008 Apr; 71(4):328-35. PubMed ID: 18284554
[TBL] [Abstract][Full Text] [Related]
9. Nociceptive sensitivity and opioid antinociception and antihyperalgesia in Freund's adjuvant-induced arthritic male and female rats.
Cook CD; Nickerson MD
J Pharmacol Exp Ther; 2005 Apr; 313(1):449-59. PubMed ID: 15608071
[TBL] [Abstract][Full Text] [Related]
10. Studies with ketamine and alfentanil following Freund's complete adjuvant-induced inflammation in rats.
Edwards SR; Mather LE; Smith MT
Clin Exp Pharmacol Physiol; 2007; 34(5-6):414-20. PubMed ID: 17439409
[TBL] [Abstract][Full Text] [Related]
11. Involvement of peripheral mu opioid receptors in scratching behavior in mice.
Yamamoto A; Sugimoto Y
Eur J Pharmacol; 2010 Dec; 649(1-3):336-41. PubMed ID: 20863827
[TBL] [Abstract][Full Text] [Related]
12. Antihyperalgesic effects of delta opioid agonists in a rat model of chronic inflammation.
Fraser GL; Gaudreau GA; Clarke PB; Ménard DP; Perkins MN
Br J Pharmacol; 2000 Apr; 129(8):1668-72. PubMed ID: 10780972
[TBL] [Abstract][Full Text] [Related]
13. Peripheral antinociceptive effects of mu- and delta-opioid receptor agonists in NOS2 and NOS1 knockout mice during chronic inflammatory pain.
Leánez S; Hervera A; Pol O
Eur J Pharmacol; 2009 Jan; 602(1):41-9. PubMed ID: 19041302
[TBL] [Abstract][Full Text] [Related]
14. Targeted nanoparticles that mimic immune cells in pain control inducing analgesic and anti-inflammatory actions: a potential novel treatment of acute and chronic pain condition.
Hua S; Cabot PJ
Pain Physician; 2013; 16(3):E199-216. PubMed ID: 23703419
[TBL] [Abstract][Full Text] [Related]
15. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain.
Schiene K; De Vry J; Tzschentke TM
J Pharmacol Exp Ther; 2011 Nov; 339(2):537-44. PubMed ID: 21816956
[TBL] [Abstract][Full Text] [Related]
16. Antihyperalgesic, Antiallodynic, and Antinociceptive Effects of Cebranopadol, a Novel Potent Nociceptin/Orphanin FQ and Opioid Receptor Agonist, after Peripheral and Central Administration in Rodent Models of Neuropathic Pain.
Tzschentke TM; Linz K; Frosch S; Christoph T
Pain Pract; 2017 Nov; 17(8):1032-1041. PubMed ID: 28112482
[TBL] [Abstract][Full Text] [Related]
17. Topical Application of Loperamide/Oxymorphindole, Mu and Delta Opioid Receptor Agonists, Reduces Sensitization of C-fiber Nociceptors that Possess Na
Uhelski ML; Bruce D; Speltz R; Wilcox GL; Simone DA
Neuroscience; 2020 Oct; 446():102-112. PubMed ID: 32858141
[TBL] [Abstract][Full Text] [Related]
18. Relative contributions of peripheral versus supraspinal or spinal opioid receptors to the antinociception of systemic opioids.
Khalefa BI; Shaqura M; Al-Khrasani M; Fürst S; Mousa SA; Schäfer M
Eur J Pain; 2012 May; 16(5):690-705. PubMed ID: 22337491
[TBL] [Abstract][Full Text] [Related]
19. Spinal antinociceptive action of loperamide is mediated by opioid receptors in the formalin test in rats.
Ray SB; Yaksh TL
Neurosci Lett; 2008 Dec; 448(3):260-2. PubMed ID: 18973791
[TBL] [Abstract][Full Text] [Related]
20. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
